131 results on '"Gronbaek H"'
Search Results
2. Markers of Fetal Growth and Serum Levels of Insulin-Like Growth Factor (IGF) I, -II and IGF Binding Protein 3 in Adults
3. Serum interleukin-4 is elevated in clinical drug-induced liver injury
4. PD-L1, tumor mutational burden, and overall survival among patients undergoing surgical treatment for hepatocellular carcinoma prior to systemic therapy
5. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF (vol 72, pg 688, 2020)
6. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
7. 1006P PD-L1, tumor mutational burden, and overall survival among patients undergoing surgical treatment for hepatocellular carcinoma prior to systemic therapy
8. Small intestinal motility in patients with neuroendocrine tumors evaluated by Motility Tracking System: 88
9. Effects of pure ethanol and alcopops on glucose, insulin, and the insulin-like growth factor system in healthy subjects
10. Orchestration of Tryptophan-Kynurenine Pathway, Acute Decompensation, and Acute-on-Chronic Liver Failure in Cirrhosis
11. Factors predicting survival in patients with high-risk acute variceal bleeding treated with pre-emptive (Early)-TIPS
12. Preemptive-TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study
13. Optimal timing of endoscopy is associated with lower 42-day mortality in variceal bleeding
14. Effect of hyperthyroidism on circulating levels of free and total IGF-I and IGFBPs in rats
15. Low free and total insulinlike growth factor I (IGF-I) and IGF binding protein-3 levels in chronic inflammatory bowel disease: partial normalization during prednisolone treatment
16. The kynurenine pathway in cirrhosis. Relationship with the development of acute decompensation and acute-on-chronic liver failure, clinical course and mortality
17. 1160O An international open-label study on safety and efficacy of 177Lu-satoreotide tetraxetan in somatostatin receptor positive neuroendocrine tumours (NETs): An interim analysis
18. Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European women
19. Plasma protein fingerprinting and machine learning for the diagnosis of small intestinal neuroendocrine tumors: The nordic NET biomarker group EXPLAIN study
20. The macrophage activation marker SCD163 and the apoptosis marker cytokeratin-18 are both predictors of disease severity in patients with Non-alcoholic Fatty Liver Disease
21. Polymorphismus in the Interleukin (IL)-1 Gene Cluster Influence the Inflammatory Burden in Patients with Decompensated Cirrhosis and Acute-On-Chronic Liver Failure
22. SAT-211 - Loss of colonization resistance in cirrhosis facilitates proton pump inhibitor-associated oralization of the colonic microbiome
23. SAT-058 - The Galactose Elimination Capacity test may monitor treatment response and disease progression in patients with Wilson Disease
24. FRI-399 - Effects of direct-acting antiviral treatment of chronic hepatitis C on macrophage activation, liver stiffness, metabolic liver function and portal hypertension in cirrhosis patients
25. THU-509 - Epigenetic modification of urea cycle enzymes in NAFLD animal models and patients: Implications for novel therapeutic approaches
26. THU-277 - Albumin administration in the prevention of hepatorenal syndrome (HRS) and death in patients with advanced cirrhosis and non-SBP infections
27. THU-250 - Combinations of inflammatory markers, soluble (s)CD163, mannose receptor (sMR) and neutrophil gelatinase associated lipocalin (NGAL), predicts mortality in patients with acute-on-chronic liver failure
28. LBP-028 - The kynurenine pathway in cirrhosis. Relationship with the development of acute decompensation and acute-on-chronic liver failure, clinical course and mortality
29. Change in soluble CD163, a marker of activated marcrophages, is associated with improvement in liver enzymes and metabolic profile in obese children during lifestyle intervention
30. Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition
31. 463P - Plasma protein fingerprinting and machine learning for the diagnosis of small intestinal neuroendocrine tumors: The nordic NET biomarker group EXPLAIN study
32. Albumin in vaginal secretion is a marker of infection
33. PT08.2: Nutritional Status and Nutritional Risk in Patients with Neuroendocrine Tumors
34. Adipose tissue insulin resistance is associated with macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease
35. FRI-466 - Soluble CD163, a Marker of Macrophage Activation, is Increased in Early Allograft Dysfunction after Liver Transplantation
36. FRI-334 - Circulating CD36 Correlates with Intrahepatic Lipid Content in Non-Alcoholic Fatty Liver Disease Patients
37. FRI-285 - Adipose Tissue Insulin Resistance is Associated with Macrophage Activation in Non-Diabetic Patients with Non-Alcoholic Fatty Liver Disease
38. THU-444 - Disease-Related Variants in Genes Involved in Bile Formation and Transport Demonstrated in 12 of 22 Patients with “Unexplained Cholestasis” by the Use of a Novel Panel for Genetic Testing
39. THU-345 - Patients with Liver Cirrhosis Have Similar Prevalence, but Higher Burden of Coronary Artery Disease Compared to Patients Evaluated for Angina Pectoris
40. THU-283 - Macrophage Activation Assessed by Soluble CD163 and Soluble Mannose Receptor is Associated with Liver Injury in Patients with Acetaminophen Overdose
41. Erratum:Octreotide prevents the early increase in renal insulin-like growth factor binding protein 1 in streptozotocin diabetic rats (Diabetes (1998) 47 (924-930))
42. Growth hormone and insulin-like growth factor-I:A suggested role in renal transplantation and graft vessel disease
43. Prognosis and staging of non-alcoholic fatty liver disease
44. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS
45. P1070 : The marker of macrophage activation soluble CD163 is associated with liver histology in children with non-alcoholic fatty liver disease
46. P1061 : The macrophage activation marker SCD163 and the apoptosis marker cytokeratin-18 are both predictors of disease severity in patients with non-alcoholic fatty liver disease
47. P1055 : The macrophage activation marker soluble CD163 is independently associated with the severity of NAFLD in morbid obesity and reduced by bariatric surgery
48. P1044 : Randomised, placebo-controlled clinical trial: Long-term resveratrol treatment for non-alcoholic fatty liver disease
49. P0974 : Effects of resveratrol on experimental non-alcoholic steatohepatitis
50. Effect of weight reduction on insulin sensitivity, sex hormone-binding globulin, sex hormones and gonadotrophins in obese children
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.